|182.72||+3.39||+1.89%||Vol 2.72M||1Y Perf 28.38%|
|Aug 2nd, 2021 16:00 DELAYED|
|- -||0.18 0.10%|
|Target Price||249.60||Analyst Rating||Strong Buy 1.50|
|Potential %||36.60||Finscreener Ranking||★ 40.56|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||☆ 34.49|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★ 44.03|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||13.54B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||41.60||Earnings Date||5th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th Aug 2021|
|Estimated EPS Next Report||-3.76|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.80M|
|Avg. Monthly Volume||3.58M|
|Avg. Quarterly Volume||4.16M|
Novavax Inc. (NASDAQ: NVAX) stock closed at 182.72 per share at the end of the most recent trading day (a 1.89% change compared to the prior day closing price) with a volume of 2.74M shares and market capitalization of 13.54B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 522 people. Novavax Inc. CEO is Stanley Charles Erck.
The one-year performance of Novavax Inc. stock is 28.38%, while year-to-date (YTD) performance is 63.86%. NVAX stock has a five-year performance of 20.05%. Its 52-week range is between 76.59 and 331.68, which gives NVAX stock a 52-week price range ratio of 41.60%
Novavax Inc. currently has a PE ratio of -19.00, a price-to-book (PB) ratio of 12.79, a price-to-sale (PS) ratio of 15.32, a price to cashflow ratio of 18.00, a PEG ratio of 2.32, a ROA of -41.60%, a ROC of -62.39% and a ROE of -121.37%. The company’s profit margin is -67.07%, its EBITDA margin is -64.00%, and its revenue ttm is $883.91 Million , which makes it $11.93 revenue per share.
Of the last four earnings reports from Novavax Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-3.76 for the next earnings report. Novavax Inc.’s next earnings report date is 05th Aug 2021.
The consensus rating of Wall Street analysts for Novavax Inc. is Strong Buy (1.5), with a target price of $249.6, which is +36.60% compared to the current price. The earnings rating for Novavax Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Novavax Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Novavax Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.87, ATR14 : 14.70, CCI20 : -80.73, Chaikin Money Flow : -0.19, MACD : -1.00, Money Flow Index : 56.17, ROC : 0.86, RSI : 43.12, STOCH (14,3) : 12.43, STOCH RSI : 0.06, UO : 36.45, Williams %R : -87.57), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Novavax Inc. in the last 12-months were: Gary C. Evans (Option Excercise at a value of $908 930), Gary C. Evans (Sold 46 125 shares of value $8 425 339 ), Gregory M. Glenn (Option Excercise at a value of $4 819 737), Gregory M. Glenn (Sold 146 656 shares of value $22 040 666 ), James F. Young (Option Excercise at a value of $885 438), James F. Young (Sold 10 000 shares of value $2 282 231 ), John A. Herrmann (Option Excercise at a value of $5 666 370), John A. Herrmann (Sold 204 481 shares of value $28 697 260 ), John J. Trizzino (Option Excercise at a value of $10 371 353), John J. Trizzino (Sold 411 769 shares of value $54 098 298 ), Michael A. Mcmanus (Option Excercise at a value of $220 800), Michael A. Mcmanus (Sold 20 000 shares of value $3 219 110 ), Rachel K. King (Option Excercise at a value of $0), Richard Douglas (Option Excercise at a value of $0), Stanley Charles Erck (Option Excercise at a value of $9 572 027), Stanley Charles Erck (Sold 195 940 shares of value $31 525 248 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.